RSPR-008

• Research type

  Research Study

• Full title

  A Double-Blind, Randomised, Placebo-controlled, Parallel Group, International, Multi-centre Phase 2 Trial Investigating the Safety and Efficacy of CRD007 in Adult Subjects with Asthma.

• IRAS ID

  193900

• Contact name

  Mimi Flensburg

• Contact email

  mimi.flensburg@rsprpharma.com

• Sponsor organisation

  RSPR Pharma AB

• Eudract number

  2015-002656-26

• Clinicaltrials.gov Identifier

  N/A, N/A

• Duration of Study in the UK

  1 years, 8 months, 0 days

• Research summary

  Asthma is a common chronic disease, affecting an estimated 300 million people(5 to 10%) world-wide, with a higher prevalence in children compared to adults. CRD007 is aimed at treating this condition by blocking mast cells from releasing chemicals (Leukotriene C4 and D4, histamines and prostaglandin) causing an allergic response, and asthmatic symptoms. This treatment aims to improve treatment options.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  15/EM/0542

• Date of REC Opinion

  22 Dec 2015

• REC opinion

  Further Information Favourable Opinion